Your session is about to expire
← Back to Search
MGTA-145 for Sickle Cell Disease
Study Summary
This trial will test a new potential medicine, MGTA-145, for sickle cell disease. It will be given with plerixafor, and the goal is to see if it can help mobilize stem cells and improve apheresis collection.
- Sickle Cell Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 25 Patients • NCT04552743Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this clinical research open to octogenarian participants?
"Based on the standards set forth by this medical trial, prospective participants must be at least 18 years old and no older than 35."
Is enrollment for this trial still accessible to interested participants?
"This research study, which was initially advertised on June 24th 2022, is actively enrolling participants. The trial information has recently been updated as of November 4th 2022."
What is the participant limit for this clinical trial?
"Affirmative, clinicaltrials.gov shows that the trial is actively enrolling participants since its launch on June 24th 2022 and last update on November 4th 2022. In total, 14 patients are needed from 3 different sites."
Has the regulatory agency sanctioned MGTA-145?
"With the existing clinical evidence supporting MGTA-145's safety, our team at Power awarded it a score of 2 on a scale from 1 to 3. This is due to this being in Phase 2 trials, indicating there is no data yet for efficacy."
What criteria must be met for someone to qualify for this clinical investigation?
"This investigation is open to 14 people aged 18-35 with sickle cell anemia. In order to be considered eligible, applicants must possess a valid diagnosis of Sickle Cell Disease, weigh at least 30 kg and fall within the specified age range."
Share this study with friends
Copy Link
Messenger